A Phase 3 bridging study of lefamulin in Chinese adults with community acquired bacterial pneumonia (CABP)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lefamulin (Primary) ; Lefamulin (Primary) ; Moxifloxacin (Primary) ; Moxifloxacin (Primary)
Indications Community-acquired pneumonia
Focus Registrational; Therapeutic Use
Sponsors Sinovant Sciences

10 Jan 2022 According to a Nabriva Therapeutics media release, the company achieved acceptance of New Drug Application by the National Medical Products Administration (NMPA) in China in November 2021.
05 Aug 2021 According to a Nabriva Therapeutics media release, Sumitomo Pharmaceuticals will file an NDA for lefamulin in China in the second half of 2021.
25 May 2021 According to a Sinovant Sciences media release, it plans to submit an NDA to Chinas NMPA as soon as possible.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com